Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer

Cancer

Volumn 120, Issue 9, 2014, Pages 1394-1400

  Kang, Hyunseok ^a   Gillespie, Theresa W ^b,c,d   Goodman, Michael ^e   Brodie, Seth A ^b,c,d   Brandes, Mina ^a   Ribeiro, Maria ^b,c,d   Ramalingam, Suresh S ^c,d   Shin, Dong M ^c,d   Khuri, Fadlo R ^c,d   Brandes, Johann Christoph ^b,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

DNA methylation; head and neck cancer; histone deacetylase (HDAC) inhibition; squamous cell carcinoma; valproic acid

Indexed keywords

VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BLADDER CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDICATION; DRUG USE; FEMALE; HEAD AND NECK CANCER; HUMAN; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIGRAINE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; SEIZURE; SMOKING; TREATMENT DURATION; UNITED STATES; VETERAN;

DNA METHYLATION; HEAD AND NECK CANCER; HISTONE DEACETYLASE (HDAC) INHIBITION; SQUAMOUS CELL CARCINOMA; VALPROIC ACID;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ENZYME INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HISTONE ACETYLTRANSFERASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK; SMOKING; UNITED STATES; VALPROIC ACID; VETERANS;

EID: 84899478904     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28479     Document Type: Article

References (47)

1. Herman JG, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349: 2042-2054.
2. McCabe MT, Brandes JC, Vertino PM,. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009; 15: 3927-3937.
3. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006; 66: 3338-3344.
4. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002; 62: 2370-2377.
5. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60: 5954-5958.
6. Alumkal JJ, Zhang Z, Humphreys EB, et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008; 72: 1234-1239.
7. Nelson WG, Yegnasubramanian S, Agoston AT, et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci. 2007; 12: 4254-4266.
8. Brandes JC, van Engeland M, Wouters KA, Weijenberg MP, Herman JG,. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis. 2005; 26: 1152-1156.
9. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007; 3: 1709-1723.
10. Hoffman AM, Cairns P,. Epigenetics of kidney cancer and bladder cancer. Epigenomics. 2011; 3: 19-34.
11. Kim YK, Kim WJ,. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol. 2009; 16: 17-22.
12. Wong TS, Gao W, Li ZH, Chan JY, Ho WK,. Epigenetic dysregulation in laryngeal squamous cell carcinoma. J Oncol. 2012;2012: 739461.
13. Ha PK, Califano JA,. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 2006; 7: 77-82.
14. Hoque MO, Kim MS, Ostrow KL, et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res. 2008; 68: 2661-2670.
15. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003; 63: 7089-7093.
16. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML,. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res. 2006; 66: 385-392.
17. Brodie SA, Li G, Al-Kommos A, et al. Class I HDACs Are Mediators of Smoke-Carcinogen Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer. Presented at American Association for Cancer Research Special Conference: Chromatin and Epigenetics in Cancer; June 19-22, 2013; Atlanta, GA.
18. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20: 6969-6978.
19. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011; 29: 1987-1996.
20. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-232.
21. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-1803.
22. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25: 3109-3115.
23. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011; 1: 598-607.
24. Sharma S, Kelly TK, Jones PA,. Epigenetics in cancer. Carcinogenesis. 2010; 31: 27-36.
25. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA,. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008; 34: 206-222.0.
26. Zullig LL, Jackson GL, Dorn RA, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. Mil Med. 2012; 177: 693-701.
27. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
28. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355: 1763-1771.
29. Hittelman WN, Liu DD, Kurie JM, et al. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst. 2007; 99: 1603-1612.
30. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008; 100: 134-139.
31. Rubin DB,. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997; 127 (8 pt 2): 757-763.
32. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
33. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008; 100: 407-420.
34. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709-720.
35. Finzer P, Ventz R, Kuntzen C, Seibert N, Soto U, Rosl F,. Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression. Virology. 2002; 304: 265-273.
36. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA. 1996; 275: 1097-1103.
37. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH,. Smoking and mental illness: a population-based prevalence study. JAMA. 2000; 284: 2606-2610.
38. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF,. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst. 2011; 103: 1342-1346.
39. Mwenifumbo JC, Tyndale RF,. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics. 2007; 8: 1385-1402.
40. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333: 1157-1160.
41. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-525. http://www.ncbi.nlm.nih.gov/pubmed?term=Cancer%20 Genome%20Atlas%20Research%20Network%5BCorporate%20 Author%5D.
42. Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013; 3: 770-781.
43. Ohta S, Uemura H, Matsui Y, et al. Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107: 81-91.
44. Calmon MF, Colombo J, Carvalho F, et al. Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet. 2007; 173: 31-37.
45. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H,. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery. 2008; 144: 956-961; discussion 961-962.
46. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H,. Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res. 2008; 148: 31-37.
47. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colon cancer. PNAS 1999; 96: 8681-6; PMID: 10411935.